On the heels of the FDA nod for Genzyme Corp.'s Campath for first-line use in chronic B-cell lymphocytic leukemia, Cephalon Inc. submitted its new drug application for the orphan drug Treanda, which targets CLL and is being developed for non-Hodgkin's lymphoma as well. (BioWorld Today)

Coming up with drugs that belong on the radar - and prescription pads - of primary-care doctors is "a challenge that biotech is treading carefully on," as Peter Hecht, CEO of Microbia Inc., told BioWorld Financial Watch last week, but Hecht's firm made a major footfall into the zone with its potential $330 million deal with Forest Laboratories Inc. (BioWorld Financial Watch)